Acute kidney injury (AKI) is associated with poor prognosis. Continuous renal replacement therapy (CRRT) is used to treat patients with AKI who are hemodynamically unstable. However, the indication for starting and stopping CRRT, the optimal CRRT dose and the choice of anticoagulants are still controversial. This study aimed to investigate the current situation of AKI treated with CRRT at Showa University Fujigaoka Hospital. This was a single-center descriptive study which included all patients who were admitted to the intensive care unit from January through December 2010 and treated for AKI with CRRT. Patient characteristics and clinical outcomes were examined, and survivors and non-survivors were compared. The study included 43 patients, (mean age, 69 years), with the most common contributing factor for AKI being sepsis (44.2%). Before beginning CRRT, 20.9%, 16.3% and 62.8% of patients were AKI stage1, 2 and 3, respectively. Continuous hemodiafiltration was the most frequent method used (81.4%). The median CRRT dose was 16ml/kg/hr. Nafamostat mesilate was used as the anticoagulant in 42 patients (97.7%). The hospital mortality was 65.1%. There were significant differences between survivors and non-survivors for mechanical ventilation (8 vs. 24;
P=0.03), urine output (0.4 vs. 0.15ml/kg/hr;
P=0.01) and AKI stage (stage 1, 4 vs. 5; stage 2, 6 vs. 1; stage 3, 5 vs. 22, respectively;
P=0.002). We surveyed the current situation for AKI patients treated with CRRT at the hospital. Non-survivors had increased mechanical ventilation, decreased urine output and a more severe AKI stage at the start of CRRT, compared with survivors.
View full abstract